Heparin and related polysaccharides: Synthesis using recombinant enzymes and metabolic engineering
Authors
Suflita, Matthew
Fu, Li
He, Wenqin
Koffas, Mattheos
Linhardt, Robert J.
ORCID
https://orcid.org/0000-0003-2219-5833
Loading...
Other Contributors
Issue Date
2015-09-22
Keywords
Biology , Chemistry and chemical biology , Chemical and biological engineering , Biomedical engineering
Degree
Terms of Use
In Copyright : this Item is protected by copyright and/or related rights. You are free to use this Item in any way that is permitted by the copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from the rights-holder(s). https://rightsstatements.org/page/InC/1.0/
Full Citation
Heparin and related polysaccharides: Synthesis using recombinant enzymes and metabolic engineering, M. Suflita, L. Fu, W. He, M. Koffas, R. J. Linhardt, Applied Microbiology and Biotechnology, 99, 7465–7479, 2015.
Abstract
Glycosaminoglycans are linear anionic polysaccharides that exhibit a number of important biological and pharmacological activities. The two most prominent members of this class of polysaccharides are heparin/heparan sulfate and the chondroitin sulfates (including dermatan sulfate). These polysaccharides, having complex structures and polydispersity, are biosynthesized in the Golgi of most animal cells. The chemical synthesis of these glycosaminoglycans is precluded by their structural complexity. Today, we depend on food animal tissues for their isolation and commercial production. Ton quantities of these glycosaminoglycans are used annually as pharmaceuticals and nutraceuticals. The variability of animal-sourced glycosaminoglycans, their inherent impurities, the limited availability of source tissues, the poor control of these source materials, and their manufacturing processes, suggest a need for new approaches for their production. Over the past decade there have been major efforts in the biotechnological production of these glycosaminoglycans. This mini-review focuses on the use of recombinant enzymes and metabolic engineering for the production of heparin and chondroitin sulfates.
Description
Applied Microbiology and Biotechnology, 99, 7465–7479
Note : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.
Note : if this item contains full text it may be a preprint, author manuscript, or a Gold OA copy that permits redistribution with a license such as CC BY. The final version is available through the publisher’s platform.
Department
The Linhardt Research Labs.
The Shirley Ann Jackson, Ph.D. Center for Biotechnology and Interdisciplinary Studies (CBIS)
The Shirley Ann Jackson, Ph.D. Center for Biotechnology and Interdisciplinary Studies (CBIS)
Publisher
Springer
Relationships
The Linhardt Research Labs Online Collection
Rensselaer Polytechnic Institute, Troy, NY
Applied Microbiology and Biotechnology
https://harc.rpi.edu/
Rensselaer Polytechnic Institute, Troy, NY
Applied Microbiology and Biotechnology
https://harc.rpi.edu/
Access
A full text version is available in DSpace@RPI